Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients

Thrombosis and Haemostasis

Volumn 103, Issue 1, 2010, Pages 160-170

  Mateos Cáceres, Petra J ^a   Macaya, Carlos ^a   Azcona, Luis ^a   Modrego, Javier ^a   Mahillo, Estela ^a   Bernardo, Esther ^a   Fernández Ortiz, Antonio ^a   López Farré, Antonio J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Aspirin resistance; Coronary ischaemia; Platelet; Proteins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TUBULIN; BETA ACTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA2 INTEGRIN; CALCIUM ANTAGONIST; CHLORIDE CHANNEL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; F ACTIN; GELSOLIN; GLUTATHIONE TRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 71; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN HEAVY CHAIN; LEUKOCYTE ELASTASE INHIBITOR; NITRATE; PYRUVIC ACID; TROPOMYOSIN; UNCLASSIFIED DRUG; VINCULIN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CELL SURVIVAL; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME ACTIVITY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE FUNCTION; WESTERN BLOTTING;

AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD PROTEINS; BLOTTING, WESTERN; CELL SURVIVAL; CYTOSKELETAL PROTEINS; DRUG RESISTANCE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENERGY METABOLISM; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OXIDATIVE STRESS; PEPTIDE MAPPING; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROTEOMICS; TREATMENT OUTCOME;

EID: 74249123585     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-05-0290     Document Type: Article

References (43)

1. Patrono C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
2. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Col Cardiol 2005; 46: 986-993.
3. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1620-1622.
4. Krasopoulos G, Brister SJ, Fraser R, et al. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
5. Crescente M, Di Castelnuovo A, Iacoviello L, et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
6. Reny JL, De Moerloose P, Dauzat M, et al. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450.
7. Kawasaki T, Ozeki Y, Igawa T, et al. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31: 591-595.
8. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006; 97: 38-43.
9. Macchi L, Sorel N, Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des 2006; 12: 251-258.
10. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
11. Freedman JE. The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation 2006; 113: 2888-2896.
12. Alonso-Orgaz S, Moreno L, Macaya C, et al. Proteomic study of plasma from moderate hypercholesterolemic patients. J Proteome Res 2006; 5: 2301-2308.
13. Sacristán D, López-Farré AJ, Zamorano-León JJ, et al. Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation. J Cardiovasc Pharmacol 2008; 51: 286-292.
14. López-Farré AJ, Mateos-Cáceres PJ, Sacristán D, et al. Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J Proteome Res 2007; 6: 2481-2487.
15. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
16. López-Farré A, Caramelo C, Esteban A, et al. Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation 1995; 91: 2080-2088.
17. Mateos-Cáceres PJ, García-Méndez A, López Farré A, et al. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 2004; 44: 1578-1583.
18. Sacristán D, Marques M, Zamorano-León JJ, et al. Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. Proteomics Clin Appl 2008; 2: 1300-1312.
19. Misset O, Opperdoes FR. Simultaneous purification of hexokinase, class-I fructose-bisphosphate aldolase, triosephosphate isomerase and phosphoglycerate kinase from Trypanosoma brucei. Eur J Biochem 1984; 144: 475-483.
20. Marques M, Sacristán D, Mateos-Cáceres PJ, et al. Different protein expression in normal and dysfunctional platelets from uremic patients. J Nephrol 2009; in press.
21. Cambria-Kiely JÁ, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002; 14: 51-58.
22. Hillarp A, Palmqvist B, Lethagen S, et al. Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003; 112: 275-283.
23. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: A review of prevalence, mechanisms and clinical significance. Thromb Haemost 2002; 88: 711-715.
24. Barkalow K, Witke W, Kwiatkowski DJ, et al. Coordinated regulation of platelet actin filament barbed ends by gelsolin and capping protein. J Cell Biol 1996; 134: 389-399.
25. Sun HQ, Yamamoto M, Mejillano M, Yin HL. Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 1999; 274: 33179-33182.
26. Spinardi L, Witke W. Gelsolin and diseases. Subcell Biochem 2007; 45: 55-69.
27. Akerman JWN, Verhoeven AJM. Platelet responses and metabolism, Vol II. CRC Press, Boca Raton FL 1987; pp. 189-213.
28. Sirover MA. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochimica Biophysica Acta 1999; 1432: 159-184.
29. Schmitz HD, Bereiter-Hahn J. Glyceraldehyde-3-phosphate dehydrogenase associates with actin filaments in serum deprived NIH3T3 cells only. Cell Biol Int 2002; 26: 155-164.
30. Gallogly MM, Mieyal JJ. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Current Opinion in Pharmacology 2007; 7: 381-391.
31. McDonagh B, Sheehan D. Effect of oxidative stress on protein thiols in the blue mussel Mytilus edulis: Proteomic identification of target proteins. Proteomics 2007; 7: 3395-3403.
32. Mosialou E, Ekström G, Adang AE, et al. Evidence that rat liver microsomal glutathione transferase is responsible for glutathione-dependent protection against lipid peroxidation. Biochem Pharmacol 1993; 45: 1645-1651.
33. Qi YX, Qu HJ. Rho-GDP dissociation inhibitor alpha downregulated by low shear stress promotes vascular smooth muscle cell migration and apoptosis: a proteomic analysis. Cardiovas Res 2008; 80: 114-122.
34. Mackenzie AB, MacKenzie AB, Mahaut-Smith MP. Chloride channels in excised membrane patches from human platelets: effect of intracellular calcium. Biochim Biophys Acta 1996; 1278: 131-136.
35. Mahaut-Smith MP. Chloride channels in human platelets: evidence for activation by internal calcium. J Membr Biol 1990; 118: 69-75.
36. Poch E, Fernández-Llama P, Botey A, et al. Parathyroid hormone and platelet cytosolic calcium concentration in essential hypertension. Nephrol Dial Transplant 1995; 10: 366-371.
37. Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest 2005; 115: 2633-2639.
38. Polla BS, Kantengwa S, Francois D, et al. Mitochondria are selective targets for the protective effects of heat shock against oxidative injury. Proc Natl Acad Sci USA 1996; 93: 6458-6463.
39. Polanowska-Grabowska R, Gear AR. Heat-shock proteins and platelet function. Platelets 2000; 1: 6-22.
40. Xanthoudakis S, Roy S, Rasper D, et al. Hsp60 accelerates the maturation of procaspase-3 by upstream activator proteases during apoptosis. EMBO J 1999; 18: 2049-2056.
41. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signalling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-490.
42. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pre-treatment.. J Am Coll Cardiol 2004; 43: 1122-1126.
43. Prabhakaran S, Wells KR, Lee VH, et al. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. Am J Neuroradiol 2008; 29: 281-285.